How are spatial assays regulated?

Depending on intended use, a spatial assay can be offered as a laboratory-developed test, self-certified by the performing laboratory, or pursued as a formally FDA-authorized in vitro diagnostic device. Complex, image-dependent diagnostics of exactly this kind have successfully completed FDA review, including through the Breakthrough Devices Program, which offers expedited engagement for devices addressing serious conditions more effectively than existing options.

What is the FDA path for a companion diagnostic?

Most companion diagnostics require a premarket approval application as a Class III device, a more rigorous process than 510(k) clearance, covered in depth elsewhere in this cluster. For genuinely novel, complex diagnostics, the Breakthrough Devices Program and the Q-Submission process for early FDA engagement, including Pre-Submission meetings limited to a maximum of four primary topics, can help clarify the applicable pathway before a full validation program begins.

What is the difference between an LDT and an IVD?

A laboratory-developed test is validated and offered by the single laboratory that developed it, historically with less direct FDA oversight, though this is changing following a 2024 FDA rule change covered elsewhere in this cluster. An FDA-authorized in vitro diagnostic device has undergone formal premarket review and can be distributed and used across multiple laboratories under that authorization. A single company can offer both simultaneously for different products within its portfolio.

Regulatory path for spatial diagnostics

Highlights in this article

Regulatory frameworks for complex assays
LDT vs. IVD routes
Analytical and clinical validation expectations
Reproducibility and standardization requirements
Engaging regulators early

Navigating spatial diagnostics regulation successfully means understanding that a spatial assay’s exact profile, complex, multi-step, and image-dependent, is precisely the profile regulators scrutinize hardest, and precisely the profile the FDA has recently built specific mechanisms to accommodate. Knowing those mechanisms early shapes a development program’s entire trajectory far more than discovering them midway through a submission.


Key takeaways An AI-powered digital pathology tool, ArteraAI Prostate, has already completed the full journey from FDA Breakthrough Device Designation to De Novo marketing authorization, offering a concrete, current map for a complex, image-dependent diagnostic. That authorization includes a Predetermined Change Control Plan permitting validation of new digital pathology scanners without a fresh 510(k) submission for each one, a specific mechanism directly relevant to spatial assays’ cross-platform compatibility question. As of December 2025, the FDA had granted 1,246 Breakthrough Device Designations but authorized only 185 devices under the program, an honest ratio worth knowing before treating designation as a guarantee. The FDA’s finalized Q-Submission Program guidance recommends a maximum of four primary topics per Pre-Submission meeting, a specific, actionable detail for engaging regulators early. The foundational LDT-versus-IVD distinction and cross-site validation mechanics are covered in depth elsewhere in this cluster rather than repeated here.

Key takeaways

An AI-powered digital pathology tool, ArteraAI Prostate, has already completed the full journey from FDA Breakthrough Device Designation to De Novo marketing authorization, offering a concrete, current map for a complex, image-dependent diagnostic.
That authorization includes a Predetermined Change Control Plan permitting validation of new digital pathology scanners without a fresh 510(k) submission for each one, a specific mechanism directly relevant to spatial assays’ cross-platform compatibility question.
As of December 2025, the FDA had granted 1,246 Breakthrough Device Designations but authorized only 185 devices under the program, an honest ratio worth knowing before treating designation as a guarantee.
The FDA’s finalized Q-Submission Program guidance recommends a maximum of four primary topics per Pre-Submission meeting, a specific, actionable detail for engaging regulators early.
The foundational LDT-versus-IVD distinction and cross-site validation mechanics are covered in depth elsewhere in this cluster rather than repeated here.

Regulatory frameworks for complex assays

A spatial assay’s complexity, multiple molecular markers, spatial relationships between them, and frequently an image-analysis algorithm interpreting the result, is exactly the combination that draws the closest regulatory scrutiny. It is also, less obviously, exactly the profile the FDA’s Breakthrough Devices Program was built to accommodate, since that program exists specifically for devices offering more effective treatment or diagnosis for serious conditions, a description that fits a genuinely novel spatial diagnostic more often than it fits an incremental improvement on an existing single-marker test.

The clearest demonstration that this pathway works for exactly this kind of assay is not hypothetical. ArteraAI Prostate, an AI-powered software that analyzes digital pathology images of a patient’s prostate cancer biopsy slide to prognosticate long-term outcomes such as 10-year risk of distant metastasis, received FDA Breakthrough Device Designation in July 2025 and subsequently received FDA De Novo marketing authorization, establishing it as an FDA-regulated Software as a Medical Device and creating a new product code category for future AI-powered digital pathology risk-stratification tools. That is a complex, multi-step, image-dependent diagnostic completing the exact regulatory journey this article maps, currently and verifiably, rather than as an abstract description of a pathway.

LDT vs. IVD routes

The foundational distinction between a laboratory-developed test, self-certified by the performing laboratory, and an FDA-authorized in vitro diagnostic device, formally reviewed and approved or cleared, is covered in depth in Spatial Biomarkers and Companion Diagnostics: The Next Frontier, including the 2024 FDA rule change affecting how laboratory-developed tests are regulated going forward. That distinction is not repeated here in detail.

What is worth noting specifically is that the ArteraAI case illustrates the two routes are not mutually exclusive within a single company’s portfolio. Even after ArteraAI Prostate’s specific software received De Novo authorization as a regulated device, Artera’s broader underlying platform remains commercially available as a laboratory-developed test through a separately offered product. A single developer can pursue formal device authorization for one specific product while continuing to offer a related, broader platform through the laboratory-developed test route, a practical structure worth understanding before assuming a program must choose one path exclusively for an entire technology platform.

Analytical and clinical validation expectations

The general analytical and clinical validation discipline a spatial biomarker must satisfy, including cross-site harmonization evidence and the specific, documented efforts that have demonstrated it is achievable, is developed in full in From Spatial Biomarker to Companion Diagnostic: The Development Path. This spoke does not repeat that content; what it adds is the honest numbers behind one specific accelerated pathway’s actual track record.


Designation is real, but authorization is the rarer outcome As of December 31, 2025, the FDA had granted 1,246 Breakthrough Device Designations and authorized 185 devices under the program for commercialization, figures that include devices previously designated under the program’s precursor. A separate 2025 analysis found that 73.3% of high-risk breakthrough devices studied were reviewed within MDUFA statutory target timeframes. Read together, those figures describe a program that delivers a genuine, documented timeline advantage once a device reaches formal review, while making clear that designation itself is considerably more common than eventual authorization. Submitting a device for designation at too early a maturity stage, essentially at concept stage before sufficient supporting evidence exists, is a documented, specific reason designation requests are denied, which argues for treating designation timing as a deliberate program decision rather than pursuing it as early as technically possible.

Designation is real, but authorization is the rarer outcome

As of December 31, 2025, the FDA had granted 1,246 Breakthrough Device Designations and authorized 185 devices under the program for commercialization, figures that include devices previously designated under the program’s precursor. A separate 2025 analysis found that 73.3% of high-risk breakthrough devices studied were reviewed within MDUFA statutory target timeframes.

Read together, those figures describe a program that delivers a genuine, documented timeline advantage once a device reaches formal review, while making clear that designation itself is considerably more common than eventual authorization. Submitting a device for designation at too early a maturity stage, essentially at concept stage before sufficient supporting evidence exists, is a documented, specific reason designation requests are denied, which argues for treating designation timing as a deliberate program decision rather than pursuing it as early as technically possible.

Reproducibility and standardization requirements

Cross-site reproducibility requirements and the specific multi-institutional harmonization efforts that have demonstrated spatial-specific metrics, not just conventional density measurements, can be standardized across independent laboratories are covered in depth in From Spatial Biomarker to Companion Diagnostic: The Development Path.

One forward-looking regulatory mechanism worth noting here specifically, since it bears directly on a spatial assay’s cross-platform standardization question, is the Predetermined Change Control Plan included in ArteraAI Prostate’s De Novo authorization. That plan grants the ability to expand platform capabilities specifically by validating compatibility with additional digital pathology scanners without requiring a further 510(k) submission for each new scanner validated. For any image-dependent spatial assay, the question of whether it performs consistently across different imaging instruments is exactly the standardization challenge this mechanism addresses directly: rather than treating every new scanner as requiring a fresh regulatory submission, a predetermined plan can define, in advance, the scope of platform expansion the agency has already agreed to accept evidence for.

Engaging regulators early

The FDA’s Q-Submission program is the specific, formal mechanism for the early regulator engagement this article’s hook describes, and it is worth understanding its actual mechanics rather than treating "engage early" as a vague piece of advice.

The FDA’s finalized May 2025 Q-Submission Program guidance recommends a maximum of four primary topics per Pre-Submission meeting, and the program covers a range of premarket interactions, including Investigational Device Exemption applications, Premarket Approval applications, Humanitarian Device Exemption applications, De Novo requests, and 510(k) submissions. Devices that have received Breakthrough Device Designation gain access to additional meeting types beyond a standard Pre-Submission, including focused, rapid-cycle Sprint discussions intended for faster iterative feedback than a standard Pre-Submission meeting allows.

Three practical scenarios make a Pre-Submission meeting specifically valuable for a spatial assay program.

Unclear regulatory classification for a genuinely novel assay type. A spatial signature combining multiple markers and a proprietary analysis algorithm may not map cleanly onto an existing device classification, and getting FDA agreement on the applicable pathway before investing in a full validation program avoids a costly later correction.
Validation and study design input before enrollment begins. Getting FDA input on study endpoints, sample size, and statistical methods for a spatial biomarker’s clinical validation study before patients are enrolled is considerably less costly than redesigning a study after data collection has already started.
Algorithm-based components specifically. A spatial assay dependent on a proprietary image-analysis or machine-learning component can use a Pre-Submission specifically to discuss validation approach and any predetermined change control plan for future algorithm updates, precisely the mechanism that benefited ArteraAI Prostate’s scanner-compatibility expansion.

Broader questions of how a regulated laboratory manages ongoing compliance once a spatial diagnostic is authorized and in routine use are addressed by our colleagues at Lab Manager in CLIA Compliance for Pre-Analytic, Analytic, and Post-Analytic Testing Phases.

For the broader convergence argument and clinical infrastructure this spoke builds on, see Translating Spatial Biology into the Clinic: Digital Pathology and Beyond, and for where this fits within the full spatial biology pipeline, Spatial Biology in Drug Discovery: From Target Discovery to Translational Medicine.

This article was produced under Drug Discovery News’s AI editorial policies.